Liraglutide : For Type 2 diabetes & Weight-Loss

For Type 2 diabetes & Weight-Loss

Liraglutide is a glucagon like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Liraglutide was approved for medical use in Europe in 2009 and in the United States in 2010. Liraglutide has the potential to acquire an important role, not only in the treatment of type 2 diabetes, but also in preservation of β-cell function and weight loss.

Liraglutide is an acylated human (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cellsurface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells.
MORE
Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs.
MORE

Global Liraglutide Market Trends

Liraglutide formulation was first approved by the U.S. Food and Drug Administration in 2010 and accounted for $418 million in sales that year. By the end of 2012, worldwide sales rose to $1.7 billion. The average retail price for Liraglutide formulation is more than $1,100 a month. By comparison, the average monthly retail price for injectable diabetes drug Byetta (exenatide), a similar drug manufactured by competitor AstraZeneca PLC, is about $905. Both drugs work to lower blood sugar by mimicking a hormone called glucagon-like peptide-1 (GLP-1).
ENTER
${specialTemplate.blobInfo_h.original_blob_name}$

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
MORE
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
MORE

Huadong Medicine provides R&D production and documentation qualifications. Echemi is mainly responsible for marketing and supply chain services.

About Huadong Medicine Co.,Ltd

Huadong Medicine Honor

China's top 10 listed pharmaceutical and medical companies · Top 10 listed pharmaceutical companies with the most investment value · China's top 500 manufacturing companies · Fortune China top 500 · China's main board listed companies top 100 · China's listed companies perform best in market value management
Strong R&D capability of Huadong Medicine

All its chemical raw medicine in production have been certified by FDA or in authoritative markets such as the European Union; its Pantoprazole Sodium Lyophilized Powder for Injection has been temporarily approvedby FDA; and its Acarbose Tablets gained access to the Austrian market in the European Union. The Company is the first Chinese medicine enterprise to achieve these results. The production lines of all of its raw medicines and some of its preparations have been certified by FDA or in authoritative markets such as the European Union.

R&D Center of Huadong Medicine

Over the years, Huadong Medicine has been continuously carrying out the technical transformation of GMP and FDA.
${specialTemplate.blobInfo_h.original_blob_name}$

For More Pharmaceutical Information



Suggestions

Email:

Message:

Send Message